News & Events

News & Events

09 November 2020

Travecta Therapeutics Appoints Jerold Chun, M.D., Ph.D. to its Scientific Advisory Board

READ MORE

11 June 2020

Travecta Therapeutics announces it has closed its oversubscribed Series A Round at $27 Million

READ MORE

Brain Transport Technology

A New Way to Treat Neurological Conditions.

Travecta Therapeutics is a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain-barrier. The company’s proprietary platform mVECTATM allows to screen and develop product candidates that can cross the blood-brain barrier targeting novel and untapped neurological pathways.

Travecta Therapeutics was founded by Dr. David Silver and Dr. Mahmood Ahmed together with the SPRIM Ventures team.

Our mVECTATM platform technology is unlocking key biological targets in neurological diseases that were previously difficult to engage because of the blood-brain barrier

– Dr. Mahmood Ahmed, Chief Scientific Officer.

mVECTATM
mVECTATM
A Powerful CNS Drug Discovery Platform
A Powerful CNS Drug Discovery Platform

Travecta’s mVECTATM proprietary platform is built upon a deep understanding of the MFSD2A transporter protein and its function at the blood-brain-barrier as well as in other key physio-pathological conditions discovered by Dr. David Silver, Professor at Duke-NUS and Scientific Founder of Travecta.

Travecta’s mVECTATM proprietary platform is built upon a deep understanding of the MFSD2A transporter protein and its function at the blood-brain-barrier as well as in other key physio-pathological conditions discovered by Dr. David Silver, Professor at Duke-NUS and Scientific Founder of Travecta.

Promising New Therapies
Promising New Therapies

Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious CNS conditions, and we are committed to selection of targets that enable a broad impact across multiple clinical indications with high unmet medical need. We focus on biological pathways that have been clinically validated but where key biological targets have not been drugged or have been inadequately drugged due to the BBB challenge. To date, we have leveraged our mVECTATM platform to design and test novel molecules with high brain penetration focused in the areas of neuropathic pain, neuro-inflammation and neuro-oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.

Our mission is to discover, develop and commercialize novel and transformative therapies that improve the lives of patients with serious CNS conditions, and we are committed to selection of targets that enable a broad impact across multiple clinical indications with high unmet medical need. We focus on biological pathways that have been clinically validated but where key biological targets have not been drugged or have been inadequately drugged due to the BBB challenge. To date, we have leveraged our mVECTATM platform to design and test novel molecules with high brain penetration focused in the areas of neuropathic pain, neuro-inflammation and neuro-oncology, and continue to apply our platform’s capabilities to additional therapeutic areas.

Solving the BBB Challenge to Treat Neurological Conditions
Solving the BBB Challenge to Treat Neurological Conditions
We are rapidly advancing a diverse pipeline of drug candidates to treat a diverse range of neurological conditions. We focus on biological pathways that have been clinically validated but where key biological targets have not been drugged or have been inadequately drugged due to the Blood-Brain Barrier.
We are rapidly advancing a diverse pipeline of drug candidates to treat a diverse range of neurological conditions. We focus on biological pathways that have been clinically validated but where key biological targets have not been drugged or have been inadequately drugged due to the Blood-Brain Barrier.